Polar Capital Holdings Plc Purchases 134,956 Shares of DexCom, Inc. (NASDAQ:DXCM)

Polar Capital Holdings Plc boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 80.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 302,456 shares of the medical device company's stock after acquiring an additional 134,956 shares during the quarter. Polar Capital Holdings Plc owned 0.08% of DexCom worth $23,522,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of DexCom by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock valued at $775,256,000 after buying an additional 56,094 shares during the last quarter. Jennison Associates LLC grew its stake in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock valued at $594,455,000 after buying an additional 710,858 shares during the last quarter. Norges Bank bought a new position in shares of DexCom during the fourth quarter valued at about $385,367,000. Northern Trust Corp grew its stake in shares of DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after buying an additional 753,857 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of DexCom by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock valued at $219,716,000 after buying an additional 91,051 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on DXCM shares. Canaccord Genuity Group raised their target price on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Mizuho started coverage on DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price on the stock. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Barclays raised their target price on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Finally, Cfra Research raised DexCom to a "hold" rating in a research note on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.11.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at $26,183,401.02. This trade represents a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Performance

DexCom stock opened at $85.67 on Friday. The stock's 50 day simple moving average is $71.70 and its two-hundred day simple moving average is $77.51. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market cap of $33.59 billion, a price-to-earnings ratio of 59.91, a PEG ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The business's revenue was up 12.5% compared to the same quarter last year. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.